Data gathered: November 23
Alternative Data for I-Mab
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 1 | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 4,000 | Sign up | Sign up | Sign up |
| Employee Rating | 86 | Sign up | Sign up | Sign up |
| Google Trends | 69 | Sign up | Sign up | Sign up |
| Patents | 9 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 1 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 947 | Sign up | Sign up | Sign up |
| Twitter Followers | 296 | Sign up | Sign up | Sign up |
| Twitter Mentions | 12 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | N/A | Sign up | Sign up | Sign up |
| Linkedin Employees | 139 | Sign up | Sign up | Sign up |
About I-Mab
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders.
| Price | $0.94 |
| Target Price | Sign up |
| Volume | 276,890 |
| Market Cap | $86M |
| Year Range | $0.94 - $1.9 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
 |
I-Mab to Participate at the Piper Sandler Healthcare ConferenceNovember 20 - Yahoo |
 |
I-Mab’s (IMAB) Buy Rating Reaffirmed at HC WainwrightNovember 19 - ETF Daily News |
 |
I-Mab Third Quarter 2024 Earnings: US$0.25 loss per share (vs US$0.57 loss in 3Q 2023)November 16 - Yahoo |
|
I-Mab Reports Third Quarter 2024 ResultsNovember 13 - Yahoo |
 |
I-Mab (IMAB) to Release Earnings on ThursdayNovember 12 - ETF Daily News |
|
I-Mab (IMAB) Scheduled to Post Quarterly Earnings on ThursdayNovember 12 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 0 | 0 | 0 | -20M | -12M | 0.000 |
| Q2 '24 | 0 | 0 | 0 | 25M | -15M | 0.000 |
| Q1 '24 | 4M | -2.9M | 4M | 21M | -85M | 0.000 |
| Q4 '23 | 0 | 0 | 0 | 0 | 0 | 0.000 |
| Q3 '23 | 4M | 0 | 4M | -346M | -276M | 0.000 |
Insider Transactions View All
No recorded Insider transactions.
Similar companies
Read more about I-Mab (IMAB) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of I-Mab?
The Market Cap of I-Mab is $86M.
What is the current stock price of I-Mab?
Currently, the price of one share of I-Mab stock is $0.94.
How can I analyze the IMAB stock price chart for investment decisions?
The IMAB stock price chart above provides a comprehensive visual representation of I-Mab's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling I-Mab shares. Our platform offers an up-to-date IMAB stock price chart, along with technical data analysis and alternative data insights.
Does IMAB offer dividends to its shareholders?
As of our latest update, I-Mab (IMAB) does not offer dividends to its shareholders. Investors interested in I-Mab should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of I-Mab?
Some of the similar stocks of I-Mab are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.